港股異動 | 三葉草生物-B(2197.HK)續升近7% 股價有望挑戰新高
格隆匯12月10日丨三葉草生物-B(2197.HK)快速拉昇漲近7%,4日連升30%。現報14.58港元有望挑戰新高價,總市值達168億港元。公司與亞盛醫藥達成臨牀合作,共同推進IAP拮抗劑APG-1387聯合重組人TRAIL-三聚體融合蛋白SCB-313治療腹膜腫瘤的臨牀開發。另外,瑞信考慮到公司新冠候選疫苗SCB-2019近期的銷量,首予其“跑贏大市”評級,目標價16.5港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.